EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cumberland Pharmaceuticals's enterprise value is $24.21 Mil.
Cumberland Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $39.55 Mil. Therefore, Cumberland Pharmaceuticals's EV-to-Revenue for today is 0.61.
The historical rank and industry rank for Cumberland Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
CPIX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.42 Med: 1.13 Max: 3.07
Current: 0.61
During the past 13 years, the highest EV-to-Revenue of Cumberland Pharmaceuticals was 3.07. The lowest was 0.42. And the median was 1.13.
CPIX's EV-to-Revenue is ranked better than 89.68% of 1027
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs CPIX: 0.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cumberland Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's EV-to-Revenue falls into.
Cumberland Pharmaceuticals's current Enterprise Value is $24.21 Mil.
Cumberland Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals's share price for today is $1.76.
Cumberland Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.75.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPIX has been successfully added to your 